Who Qualifies for GLP-1 Weight Loss?
BMI thresholds, comorbidities, contraindications — a clear breakdown of who is a candidate for semaglutide or tirzepatide and who is not.
GLP-1 medications are powerful tools, but they are not appropriate for everyone. Clear, evidence-based criteria determine who benefits and who should choose a different path.
FDA-approved criteria
For weight management, semaglutide (Wegovy) and tirzepatide (Zepbound) are approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea.
Why a comorbidity matters at BMI 27–29
At BMI 27, the absolute health risk from excess weight is modest. The presence of a weight-related condition signals that the metabolic strain is real — and that pharmacological intervention is justified.
Absolute contraindications
GLP-1 receptor agonists should not be used in patients with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), known hypersensitivity to the drug, pregnancy, or active pancreatitis.
Relative contraindications
A history of gallbladder disease, gastroparesis, severe GI motility disorders, or diabetic retinopathy requires careful evaluation. These are not absolute blocks, but they shift the risk-benefit calculation.
What about cosmetic weight loss?
Patients with a BMI under 27 are generally not candidates for GLP-1 therapy. The risk-benefit profile does not favor pharmacological intervention for purely aesthetic goals, and reputable clinicians will decline these requests.
How Valora evaluates eligibility
Every Valora intake includes a comprehensive medical history, family history, current medications, and a recent comprehensive metabolic panel. A licensed physician reviews each case before any prescription is written.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.FDA Prescribing Information: Wegovy (semaglutide) injection.— U.S. Food and Drug Administration, 2021.
- 2.FDA Prescribing Information: Zepbound (tirzepatide) injection.— U.S. Food and Drug Administration, 2023.
- 3.Garvey WT et al. AACE Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity. Endocr Pract. 2016;22:1-203.— American Association of Clinical Endocrinologists, 2016.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
